Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mutations may diminish
vaccine-induced protective immune responses, particularly as antibody titers wane over …

Two and a half years into the COVID-19 pandemic, we have gained many insights into the
human antibody response to the causative SARS-CoV-2 virus. In this Review, we …

Antibody-based therapeutics and vaccines are essential to combat COVID-19 morbidity and
mortality after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection …

Understanding the molecular basis for immune recognition of SARS-CoV-2 spike
glycoprotein antigenic sites will inform the development of improved therapeutics. We …

Transmission of SARS-CoV-2 is uncontrolled in many parts of the world; control is
compounded in some areas by the higher transmission potential of the B. 1.1. 7 variant …

A novel variant of concern (VOC) named CAL. 20C (B. 1.427/B. 1.429), which was originally
detected in California, carries spike glycoprotein mutations S13I in the signal peptide …

The Delta variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has
outcompeted previously prevalent variants and become a dominant strain worldwide. We …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) B. 1.1. 7 and B. 1.351
variants were first identified in the United Kingdom and South Africa, respectively, and have …

The germinal centre (GC) response is critical for the generation of affinity-matured plasma
cells and memory B cells capable of mediating long-term protective immunity …

The emergence of SARS-CoV-2 variants has raised concerns about altered sensitivity to
antibody-mediated immunity. The relative resistance of SARS-CoV-2 variants B. 1.1. 7 and …